Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) saw unusually-high trading volume on Monday . Approximately 571,514 shares were traded during mid-day trading, an increase of 27% from the previous session’s volume of 449,303 shares.The stock last traded at $11.93 and had previously closed at $11.97.

MNTA has been the subject of several analyst reports. Zacks Investment Research upgraded Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, April 27th. Leerink Swann restated an “outperform” rating and set a $18.00 price target (down from $21.00) on shares of Momenta Pharmaceuticals in a research report on Wednesday, May 4th. Brean Capital restated a “buy” rating and set a $19.00 price target on shares of Momenta Pharmaceuticals in a research report on Wednesday, May 4th. JPMorgan Chase & Co. restated a “buy” rating on shares of Momenta Pharmaceuticals in a research report on Wednesday, May 4th. Finally, Goldman Sachs Group Inc. initiated coverage on Momenta Pharmaceuticals in a research report on Monday, June 6th. They set a “neutral” rating and a $14.00 price target for the company. Five investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $17.80.

The stock’s 50-day moving average price is $11.40 and its 200-day moving average price is $10.39. The company’s market capitalization is $827.28 million.

Momenta Pharmaceuticals (NASDAQ:MNTA) last announced its quarterly earnings results on Thursday, August 4th. The biotechnology company reported ($0.31) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.01. The business had revenue of $26.40 million for the quarter, compared to analysts’ expectations of $23.55 million. During the same period last year, the company posted ($0.04) earnings per share. The firm’s revenue for the quarter was down 41.2% on a year-over-year basis. Equities research analysts anticipate that Momenta Pharmaceuticals Inc. will post ($1.25) EPS for the current year.

In related news, President Craig A. Wheeler sold 5,880 shares of the company’s stock in a transaction on Friday, May 20th. The shares were sold at an average price of $10.18, for a total transaction of $59,858.40. Following the completion of the sale, the president now directly owns 349,521 shares of the company’s stock, valued at approximately $3,558,123.78. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

A number of hedge funds have made changes to their positions in MNTA. Morgan Stanley boosted its stake in shares of Momenta Pharmaceuticals by 123.0% in the fourth quarter. Morgan Stanley now owns 69,759 shares of the biotechnology company’s stock worth $1,035,000 after buying an additional 38,470 shares during the period. New York State Common Retirement Fund boosted its stake in shares of Momenta Pharmaceuticals by 2.0% in the fourth quarter. New York State Common Retirement Fund now owns 150,991 shares of the biotechnology company’s stock worth $2,241,000 after buying an additional 2,900 shares during the period. California Public Employees Retirement System boosted its stake in shares of Momenta Pharmaceuticals by 2.9% in the fourth quarter. California Public Employees Retirement System now owns 200,600 shares of the biotechnology company’s stock worth $2,977,000 after buying an additional 5,600 shares during the period. Rhumbline Advisers boosted its stake in shares of Momenta Pharmaceuticals by 9.9% in the fourth quarter. Rhumbline Advisers now owns 75,638 shares of the biotechnology company’s stock worth $1,122,000 after buying an additional 6,835 shares during the period. Finally, Swiss National Bank boosted its stake in shares of Momenta Pharmaceuticals by 2.6% in the fourth quarter. Swiss National Bank now owns 91,500 shares of the biotechnology company’s stock worth $1,358,000 after buying an additional 2,300 shares during the period.

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. It focuses on three product areas: Complex Generics, Biosimilars and Novel Therapeutics. It has developed generic version of Lovenox (enoxaparin sodium injection).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.